Malaria Respiratory Paediatrics
Conditions
Interventions
Group 1
Group 2
Sponsors
Barcelona Institute for Global Health
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Parents/guardians have signed the informed consent • Permanent residence in the study area-health facility catchment area • Without known allergies to or contraindications to macrolides • Without known allergies to or contraindications to SP • Agreement to complete the EPI scheme at the recruitment health facility • Parents/guardians agree to participate
Exclusion criteria
Exclusion criteria: • Residence outside the study area or planning to move out in the following 12 months from enrolment • Known history of allergy or contraindications to macrolides and/or SP • Known history of allergy or contraindications to SP • With signs of any acute illness at the time of recruitment • Participating in other intervention studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| The cause-specific mortality rate ;Malaria-related mortality ;Incidence of all-cause hospital admissions;Incidence of all-cause outpatient attendances;Incidence of confirmed (RDT positive) malaria outpatient attendances;Incidence of confirmed (blood smear positive) malaria hospital admissions;Frequency and severity of drug adverse reactions;Prevalence of SP resistance in U5 children;Prevalence of macrolide resistance in nasopharyngeal isolates;Prevalence of macrolide resistance in the gut bacteria;The proportion of children with protective antibody responses to specific routine EPI immunisations (measles and yellow fever) | — |
Countries
Sierra Leone
Contacts
Public ContactAnna Lucas
Project Manager
Outcome results
None listed